BRPI0717348A2 - COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES - Google Patents

COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES

Info

Publication number
BRPI0717348A2
BRPI0717348A2 BRPI0717348-2A2A BRPI0717348A BRPI0717348A2 BR PI0717348 A2 BRPI0717348 A2 BR PI0717348A2 BR PI0717348 A BRPI0717348 A BR PI0717348A BR PI0717348 A2 BRPI0717348 A2 BR PI0717348A2
Authority
BR
Brazil
Prior art keywords
captecine
proteases
inhibit
compositions
processes
Prior art date
Application number
BRPI0717348-2A2A
Other languages
Portuguese (pt)
Inventor
Robert Epple
Original Assignee
Irm Llc
Russo Ross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Russo Ross filed Critical Irm Llc
Publication of BRPI0717348A2 publication Critical patent/BRPI0717348A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0717348-2A2A 2006-10-23 2007-10-17 COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES BRPI0717348A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86250006P 2006-10-23 2006-10-23
PCT/US2007/081635 WO2008051763A1 (en) 2006-10-23 2007-10-17 Cathepsin proteases inhibitors

Publications (1)

Publication Number Publication Date
BRPI0717348A2 true BRPI0717348A2 (en) 2013-10-15

Family

ID=39091868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717348-2A2A BRPI0717348A2 (en) 2006-10-23 2007-10-17 COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES

Country Status (9)

Country Link
EP (1) EP2078027A1 (en)
JP (1) JP2010507681A (en)
KR (1) KR20090064463A (en)
CN (1) CN101589047A (en)
AU (1) AU2007309195A1 (en)
BR (1) BRPI0717348A2 (en)
CA (1) CA2667816A1 (en)
MX (1) MX2009004290A (en)
WO (1) WO2008051763A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923225A2 (en) 2008-12-02 2016-10-04 Chiralgen Ltd Phosphorus-modified nucleic acid synthesis method
BR112012000828A8 (en) 2009-07-06 2017-10-10 Ontorii Inc NEW NUCLEIC ACID PRO-DRUGS AND METHODS OF THEIR USE
WO2012039448A1 (en) 2010-09-24 2012-03-29 株式会社キラルジェン Asymmetric auxiliary group
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
PT2872485T (en) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Asymmetric auxiliary group
RU2015104762A (en) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. CHIRAL CONTROL
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
KR20230152178A (en) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 Chiral design
US10017463B2 (en) 2014-07-21 2018-07-10 Brandeis University Inhibitors of deubiquitinating proteases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
MX2009004290A (en) 2009-07-27
WO2008051763A1 (en) 2008-05-02
KR20090064463A (en) 2009-06-18
CN101589047A (en) 2009-11-25
EP2078027A1 (en) 2009-07-15
AU2007309195A1 (en) 2008-05-02
JP2010507681A (en) 2010-03-11
CA2667816A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
SMAP200900058A (en) Compounds and compositions as proteinachinase inhibitors
SM201000108B (en) Compounds and compositions as proteinachinase inhibitors
SMAP200900020A (en) Compounds and compositions as proteinachinase inhibitors
SMAP200900031A (en) Compounds and compositions as proteinachinase inhibitors
BRPI0717348A2 (en) COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES
LTPA2017010I1 (en) Protease inhibitors
BRPI0915073A2 (en) compositions and methods comprising variant microbial proteases
BRPI0716325A2 (en) ANTIMICROBIAN COMPOSITION
BRPI0815407A2 (en) COMPOSITIONS AND METHODS TO CONTROL NEMATOIDS
FR2899479B1 (en) CICATRISANTE COMPOSITION
BRPI0922084A2 (en) COMPOSITIONS AND METHODS UNDERSTANDING SERINA PROTEASE VARIANTS
BRPI0717460A2 (en) CHK1 INHIBITOR COMPOSITIONS
DK1940839T3 (en) Pyridopyrimidione Inhibitors of P13Ka
DK1989206T3 (en) E1 activating enzyme inhibitors
DK2041138T3 (en) PYRROLTRIAZINKINASE INHIBITORS
DK2024375T3 (en) Cyclopropyl-condensed indolobenzazepine-HCV-NS5B inhibitors
DE602008005353D1 (en) Light-scattering compositions
BRPI0716881A2 (en) TOPIC COMPOSITIONS
DK1849352T3 (en) combine
BRPI0718428A2 (en) IBUPROPHEN COMPOSITION
DK1888024T3 (en) Topical compositions
DK2104535T3 (en) Compounds and Compositions as Channel Activating Protease Inhibitors
BRPI0811430A2 (en) Anti-Insomnia Compositions and Processes
DK2066662T3 (en) SERINHYDROLASE INHIBITORS
DOP2009000144A (en) COMPOSITION OF SUSTAINED RELEASE AND METHODS TO PRODUCE THE SAME

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired